

Declaration of Interests Register

TA Committee C

Publication Date: 9 December 2020

Topic: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Michael Chambers	TA Committee C Member	Financial Interest	Michael has recently been involved in running a training programme (co-ordinated by the University of Utrecht) on Real World Evidence for Roche pharmaceuticals, manufacturer of a possible comparator therapy. This has not involved discussion of any specific Roche products.	N/A	14.07.2020	N/A	It was agreed that this declaration would not prevent Michael Chambers participating in discussions on this topic.
Prithwiraj Das	TA Committee C Member	Non-Financial & Personal Interests	Prithwiraj works at the pharmaceutical company Boehringer Ingelheim Ltd (BI) and currently works as the Market Access Lead on the Speciality Medicines (Oncology, Inflammation, Thrombolysis) in the UK and Ireland. BI may have various early-phase	N/A	19.07.2020	N/A	It was agreed that this declaration would not prevent Prithwiraj Das participating in discussions on this topic.

			molecules in the pipeline. He has not been involved in work in these indications in the last 12 months.				
Richard Nicholas	TA Committee C Member	Non-Financial & Personal Interests	Richard has attended advisory boards and undertaken trials using ocrelizumab (Roche) for multiple sclerosis.	N/A	19.07.2020	N/A	It was agreed that this declaration would not prevent Richard Nicholas participating in discussions on this topic.
Peter Hillmen	Clinical Expert	Direct Financial and Non-Financial Interests	1. Has received honoraria from AbbVie for participation in an advisory board. 2. Research Support from AbbVie for clinical trials run in the UK.	N/A	29.08.2019	N/A	It was agreed that this declaration would not prevent Peter Hillmen from participating in part 1 discussions on this topic.
Jackie Martin	Patient Expert	Non-Financial & Personal Interests	Jackie is a patient with CLL undergoing treatment with Ibrutinib as a participant in the FLAIR clinical trial.	N/A	19.08.2019	N/A	It was agreed that this declaration would not prevent Jackie Martin from participating in part 1 discussions on this topic.
Anna Schuh	Clinical Expert	Direct Financial & Non-Financial Interests	1. Has received honoraria for giving education talks from Abbvie, Roche, Janssen, and Gilead in the last two years. 2. Is a PI on the Abbvie study M13-982 which was the study evaluating	N/A	13.08.2019	N/A	It was agreed that this declaration would not prevent Anna Schuh from participating in part 1 discussions on this topic.

			venetoclax in patients with del17 CLL.				
Nick York	Patient Expert	Direct Financial, Non-Financial, interests	1. Employee of Leukaemia Care and Chair of the CLL Advocates Network (CLLAN), which also receives funding from pharmaceutical companies. 2. Is a patient with CLL.	N/A	08.08.2019	N/A	It was agreed that this declaration would not prevent Nick York from participating in part 1 discussions on this topic.